慢性肺病的可吸入核酸治疗药物:进展,挑战和前景
Yangeng Wang1, Wenzhe Xuan1, Chengqiong Mao2
1School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, PR China.
Acta biomaterialia
|August 2, 2025
概括
吸入性核酸疗法为慢性肺部疾病 (如COPD和喘) 提供了新的希望. 开发有效的输送系统是克服肺部障碍和推进呼吸道疾病基因治疗的关键.
科学领域:
- 肺部药物输送 肺部药物输送
- 基因治疗 基因治疗
- 纳米医学是一种纳米医学.
背景情况:
- 慢性肺部疾病 (喘,COPD,CF,IPF) 导致显著的发病率和死亡率.
- 目前的治疗方法缺乏针对疾病发病的分子水平向.
- 核酸疗法提供精确的基因调节和途径调节.
研究的目的:
- 对慢性肺部疾病的可吸入核酸输送平台的最新进展进行审查.
- 讨论肺部生物障碍和克服它们的策略.
- 概述吸入基因疗法的临床进展和未来方向.
主要方法:
- 关于可吸入核酸输送系统的最新科学文献的审查.
- 对纳米载体设计 (病毒,脂质,聚合物,混合) 的分析.
- 讨论肺微环境中的生理和病理障碍.
主要成果:
- 可吸入的核酸输送可直接,非侵入性地进入肺部,具有局部效应.
- 各种纳米载体被设计为改善核酸稳定性,准和转染.
- 克服肺部障碍物 (粘液,酶,巨细胞) 对于疗效至关重要.
结论:
- 吸入型核酸输送系统在治疗慢性肺部疾病方面表现有前途.
- 有效的纳米载体设计和对肺壁垒的理解对于临床转化至关重要.
- 需要进一步的研究,以加快对呼吸系统疾病的吸入基因疗法的发展.
相关概念视频
Inhaled Medications
394
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
394
Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K
Drugs Used in Lower Respiratory Disorders: Overview
583
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
583
Chronic Obstructive Pulmonary Disease
1.4K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.4K
Chronic Obstructive Pulmonary Disease-I: Introduction
2.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.9K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.1K


